[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Meningitis Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 30 pages | ID: MFB3A3209B73EN
VPAResearch

US$ 1,699.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Meningitis Drug pipeline report- 2020 is an annual R&D review of Meningitis pipeline candidates. The report presents the current status of all major Meningitis therapeutic compounds. Detailed insights into Meningitis pipeline development, current status, companies, drug profiles and Meningitis preclinical and clinical trials are included.

2020 Meningitis Pipeline Market Insights
Meningitis disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Meningitis therapies, pipeline by phase and others are included.

Meningitis pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Meningitis Therapeutic Drug candidates
Both active and inactive Meningitis pipeline drug candidates are included in the report

Meningitis Clinical Trials and preclinical Studies
Meningitis In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Meningitis pipeline market developments
Meningitis Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Meningitis pipeline companies in active development
The report analyzes Meningitis pipeline of the below companies-

Eubiologics Co Ltd, Matinas BioPharma Holdings Inc, Olymvax Biopharmaceuticals Inc, Serum Institute of India Ltd, TGV Therapeutics, Viamet Pharmaceuticals Inc

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
6 Companies investing in Meningitis pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Meningitis pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. MENINGITIS PIPELINE MARKET INSIGHTS, 2020

1.1 Meningitis Disease Overview
1.2 Meningitis Drug Pipeline Snapshot, 2020
  1.2.1 Meningitis Pipeline Drugs by Phase
  1.2.2 Meningitis Pipeline Drugs by Company
  1.2.3 Meningitis Pipeline Drugs by Mechanism of Action
  1.2.4 Meningitis Pipeline Drugs by Route of Administration

2. MENINGITIS COMPANY WISE PIPELINE DETAILS

Eubiologics Co Ltd Meningitis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Matinas BioPharma Holdings Inc Meningitis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Olymvax Biopharmaceuticals Inc Meningitis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Serum Institute of India Ltd Meningitis Pipeline Drugs
  Company Profile
  Drug Candidate Details
TGV Therapeutics Meningitis Pipeline Drugs
  Company Profile
  Drug Candidate Details
Viamet Pharmaceuticals Inc Meningitis Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. MENINGITIS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. MENINGITIS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications